Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease.

ABSTRACT:

Background

Higher-than-normal levels of circulating triglycerides are a risk factor for ischemic cardiovascular disease. Activation of lipoprotein lipase, an enzyme that is inhibited by angiopoietin-like 4 (ANGPTL4), has been shown to reduce levels of circulating triglycerides.

Methods

We sequenced the exons of ANGPTL4 in samples obtain from 42,930 participants of predominantly European ancestry in the DiscovEHR human genetics study. We performed tests of association between lipid levels and the missense E40K variant (which has been associated with reduced plasma triglyceride levels) and other inactivating mutations. We then tested for associations between coronary artery disease and the E40K variant and other inactivating mutations in 10,552 participants with coronary arter

SUBMITTER: Dewey FE 

PROVIDER: S-EPMC4900689 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature